Call for Proposals
The PolG Foundation is a newly established 501(c)(3) nonprofit organization. The mission of the Foundation is to support and to accelerate research to find effective treatments and a cure for PolG mitochondrial disorders.
The PolG Foundation provides grant funding to investigators of basic science, clinical trial research and development of novel therapies for PolG mitochondrial disorders in both pediatric and adult PolG patients.
The PolG Foundation seeks to fund research projects of up to $250.000 p/y (maximum 5 year research projects) that will have direct impact on drug discovery and clinical development of PolG therapeutics. The principal investigator may only submit one letter of intent per year.
If you have a Breakthrough Research Initiative that does not fit into the criteria mentioned in this call for proposals, particularly when the therapeutic approach has disease-modifying potential, we encourage you to register here. Our team will get in touch to further discuss your proposal.
You will use the Pre-clinical or Clinical proposal format that can be found on the Foundation’s website under Call for Proposals. A detailed financial statement is required. Indicate if statistical consulting services are available to you. If not, briefly state why they are not available. Proposals not adhering to these guidelines will be returned without review.
All proposals and requested supporting documentation should be submitted via email to firstname.lastname@example.org.
Proposal deadline is February 1, 2023. Applicants will be notified regarding the status of their proposal by May 1, 2023.
We look forward to evaluating your exciting and innovative projects.
The PolG Foundation Grants
Basic science: understanding mechanisms and modelling PolG disease.
- Understanding the pathophysiology and how this can be manipulated for therapeutic intervention
- Generating models that mimic human disease
Development of Novel Therapies
- New therapeutic approaches to improve PolG function
- Gene therapies
- Development of drugs and/or repurposing of drugs to improve the biochemical and genetic defects seen in PolG disease. Special focus on, but not limited to:
- Nucleotide metabolism
- Innate Immunity
- NAD+ availability
- Pilot studies & full clinical trials